CDC warns travelers of higher measles risk
A total of 14 outbreaks have been reported this year, with 16 through the entire 2024. An outbreak is considered three or more related cases. Photo by Airman 1st Class Matthew Lotz/U.S. Air Force
May 30 (UPI) -- The Centers for Disease Control and Prevention is warning people about the risks of contracting measles while traveling.
The federal health agency updated its guidance Wednesday after reports from those flying within the United States contracting the highly contagious virus. The number of cases in the United States is the highest since 2000 after the debut of the vaccination program.
Of the 1,088 measles cases reported so far this year, 96% were unvaccinated.
"Travelers can catch measles in many travel settings including travel hubs like airports and train stations, on public transportation like airplanes and trains, at tourist attractions, and at large, crowded events," the agency said.
About 90% of confirmed cases are linked to outbreaks within the United States, and not travel outside the country, the CDC said.
Cases have been reported in all but 18 states this year, the CDC said Friday. New York and New York City are listed separately among the 33 jurisdictions listed.
Two more states -- Iowa and Nebraska -- reported their first confirmed cases this week.
Texas, where the first outbreak was reported in January, leads with 225 infections. There were 285 cases in 2024 with the highest since 2000 in 2019 with 1,274.
Three deaths have been reported.
Of the cases, 30% are children under 5, 37% 5-19 years old, 32% 20 years and older.
The CDC has received at least 62 reports of travelers contagious with the highly transmissible virus while flying into the U.S. or within the country, a spokesperson for the CDC told CBS News in a statement.
The agency investigated 50 of those travelers, and determined that measles spread during air travel in at least one of those situations, the spokesperson said. The CDC connected confirmed cases of measles among airline passengers sitting near each other.
Unvaccinated U.S. residents are infecting those on aircraft, the CDC said.
"International travelers are at risk of measles if they have not either been fully vaccinated at least two weeks prior to departure OR had measles in the past," the CDC said.
The agency urges all international travelers should be fully vaccinated against measles with the measles-mumps-rubella, or MMR, vaccine, according to CDC's recommendations. These include a dose for infants 6-11 months old, and at least 28 days apart for anyone 12 months old or older without adequate evidence of immunity.
Also in the update, the CDC dropped its list of countries facing "high incidence" of measles. The agency now warns only that the virus is "an ongoing risk around the world, and more international travelers are getting infected."
A total of 14 outbreaks have been reported this year, with 16 through the entire 2024. An outbreak is considered three or more related cases.
Measles was declared eliminated from the United States in 2000 after the debut of the vaccination program, meaning there is no measles spreading within the country and new cases are only found when someone contracts measles abroad and returns to the country.
Before then, nearly every child got measles by the time they were 15.
The measles vaccine was first licensed for public use in 1963, according to the WHO.
The first MMR vaccine was administered in 1971.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
19 minutes ago
- UPI
FDA OKs new Moderna COVID-19 vaccine for 65+, others with conditions
A vial of the Moderna COVID-19 vaccine in the Meuhedet Clinic in Jerusalem on January 3, 2022. The FDA approved a new version of the vaccine on Friday. File photo by Debbie Hill/UPI | License Photo May 31 (UPI) -- The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened vaccine standards for the virus. The FDA announced Friday that mNEXSPIKE can be given to adults 65 and older and those 12 to 64 with at least one underlying condition that could put them at risk of severe infection. Recipients also must have been previously vaccinated for COVID-19. The company, headquartered in Cambridge, Mass., said Saturday it expects to have the vaccine available for the 2025-2026 respiratory virus season. Moderna also produces Spikevax for COVID-19, and mRESVIA for the respiratory syncytial virus, or RSV. "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," Stéphane Bancel, chief executive officer of Moderna, said. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." STAT reported the next-generation COVID-19 vaccine uses a refined target to generate antibodies against the SARS-CoV-2 virus. The dose is one-fifth the doage used in Spikevax, the current vaccine. Moderna conducted a randomized, observer-blind Phase 3 clinical trial of approximately 11,400 participants aged 12 years and older to test the mRNA-1283. The primary efficacy was to demonstrate the vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared with Spikevax, Moderna's updated COVID-19 vaccine approved on Sept. 6, 2024. The new vaccine showed a 9.3% higher relative vaccine efficacy than the mRNA-1273 in individuals aged 12 years and older. It was 13.5% better in adults aged 65 and older. In the Phase 3 trial, the most common side effects were injection site pain, fatigue, headache and myalgia. The company said there is a very small chance that mNEXSPIKE could cause a severe allergic reaction, usually within a few minutes to 1 hour after getting a dose of mNEXSPIKE. Myocarditis, which is inflammation of the heart muscle, and pericarditis, which is inflammation of the lining outside the heart, have occurred in some people who have received mRNA COVID-19 vaccines, Moderna said. Of those with problems, they are among males12 through 24. The FDA has asked Moderna to conduct post-marketing studies to continue to evaluate the safety and effectiveness of the product. This includes a study on the outcomes of pregnant people and their babies when the vaccine was administered during pregnancy. The study is to be submitted by the end of 2032. Pfizer was the first COVID-19 vaccine to receive emergency approval in December 2020 and Moderna was followed one week later. The first COVID-19 cases were reported in the United States in January 2020. The FDA first granted Pfizer-BioNTech full COVID-19 approval for those 12 and older in August 2021 and Moderna in January 2022. They remain available under emergency use authorization for children as young as 6 months. On Friday, the Centers for Disease Control and Prevention said children without underlying health conditions "may receive" a COVID-19 vaccine, contradicting a directive by Health and Human Services Secretary Robert F. Kennedy Jr. earlier in the week. The CDC updated the childhood immunization schedule published late Thursday. Kennedy, who said the agency would stop recommending the shots for healthy children, noted the guidelines would be changed. The new schedule also requires health insurance companies, Medicare and Medicaid plans to continue to cover the vaccines for children. COVID-19 shots during pregnancy are listed as "No Guidance/Not Applicable," where they were previously recommended for all pregnant adults. Earlier this month, the FDA approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay. The agency approved the vaccine only for people 65 and older and those 12 and older with at least one underlying condition at a higher risk of severe illness. This week, HHS notified Moderna that it was canceling contracts worth $766 million to develop, test and license vaccines for flu subtypes that could trigger future pandemics, including the dangerous H5N1 bird flu virus. The first COVID-19 case was reported in the United States on Jan. 20, 2020. About 23% of U.S. adults are estimated to be up to date with the vaccine, according to the CDC through April. For children 6 months and up to 18, it is an estimated 13.%, the CDC reported.
Yahoo
29 minutes ago
- Yahoo
Ship with aid bound for Gaza readies to set sail to break Israeli blockade
June 1 (UPI) -- A ship filled with aid bound for Gaza readied to set sail Sunday, hoping to break Israel's blockade on the Palestinian enclave a month after another of its ships was damaged in an alleged Israeli drone strike in Maltese waters. The Freedom Flotilla Coalition was expected to set sail Sunday on a ship called the Madleen from Malta with activists onboard, including Greta Thunberg; celebrity artists Brian Eno and Nan Goldin; actors Susan Sarandon, Guy Pearce, Aiysha Hart, Liam Cunningham, and Indya Moore; and Alana Hadid, the daughter of Palestinian-Jordanian real estate developer Mohamed Hadid, among others. The ship is carrying "as much life-saving aid as she can carry," including baby formula and medical supplies. Its organizers have stressed that the ship is not carrying any weapons. Organizers have installed a tracking device on the ship so that the public can view its progress, noting that "the risk is real." They hope that the tracker can help increase its safety, accountability and solidarity with their mission. A similar flotilla was raided by the IDF in May 2010, leading to the close-range shooting deaths of at least nine passengers in international waters. "Unarmed and nonviolent, 'Madleen' poses no threat. She sails in full accordance with international law," the Freedom Flotilla Coalition said in a statement on Telegram. "Any attack or interference will be a deliberate, unlawful assault on civilians." Last month, another ship called the Conscience put out an SOS distress signal when it was 16 miles off the coast of Malta. "The front of the vessel was targeted twice, resulting in a fire and a breach in the hull," the group said at the time. "We have sent an SOS distress signal out, but no one has responded. Water is coming into the ship."
Forbes
4 hours ago
- Forbes
Subtle Differences Emerge Between FDA And CDC On COVID Vaccine Advice
An illustration picture shows vials with Covid-19 vaccine stickers attached and syringes with the ... More logo of the company Novavax. (Photo by JUSTIN TALLIS / AFP) (Photo by JUSTIN TALLIS/AFP via Getty Images) In a major policy shift last month, Food and Drug Administration officials proposed requiring new clinical trial research with respect to the effectiveness of COVID-19 vaccines in healthy people under 65, including pregnant women, before issuing an updated approval for a broader population. At the same time, in an update to its immunization schedule posted May 29th, the Centers for Disease Control and Prevention include the option of COVID-19 vaccines for healthy children and pregnant women. Based on the language used by CDC, it suggests the agency aims for a shared decision-making approach in which individuals consult with their doctor prior to getting a shot. We witnessed a preview of the new FDA approach when the agency made an unusual decision to limit the approval of the nation's only non-mRNA coronavirus vaccine, Novavax's nuvaxovid, for use only in adults 65 and older or those 12 to 64 who have at least one health problem that puts them at increased risk from COVID-19. To be indicated for a broader population, the FDA plans to require that vaccine makers conduct booster trials to demonstrate effectiveness in people under 65 or without certain risks. These trials could take a year to complete, according to a STAT report. As such, it's not something that can be accomplished prior to the autumn, even if Novavax, Pfizer, or Moderna, wished to pursue this pathway. Similar to annual flu shots, which adapt to new strains, COVID-19 boosters update immunity to target evolving variants. Data from several years of booster campaigns show lower hospitalization and death rates for boosted individuals compared to unvaccinated people or those who haven't gotten boosters. This particularly applies to the vulnerable subpopulations, stratified by age and underlying health conditions. The COVID-19 vaccines, both mRNA and non-mRNA, are recommended for anyone who is over 65 or who has a medical condition that can increase the risk of severe illness or death. Underlying conditions include, among other things, obesity, 'physical inactivity,' diabetes, clinical depression and being immunocompromised. It's estimated that between 100 and 200 million Americans will still be eligible for vaccination due to having such health issues. Nevertheless, this raises questions for people who don't have underlying health conditions and are under 65 but would like to get a COVID-19 shot this fall. The FDA and CDC appear to differ subtly in terms of their current advice for healthy individuals under 65. Is it possible for these folks to obtain a jab at the pharmacy with no questions asked? Or will they have to go to their doctor and be granted de facto permission to get the shot? Perhaps equally important, will their insurer pay for it? As the New York Times explains, insurance companies may serve as the 'gatekeepers by demanding medical documentation of an underlying condition before agreeing to cover the cost.' The out-of-pocket cost to patients could be as much $140 a shot. Top FDA officials Prasad and Makary advocate an 'evidence-based' approach to COVID-19 vaccination. They also write of aligning policy with Europe. Indeed, in most instances, European public health authorities have adopted a targeted approach that aims at ensuring the elderly and those with underlying health conditions get boosted. This means that outreach campaigns in European countries only target subpopulations for which the vaccine is recommended by the respective public health authority. This is unlike the universal recommendations previously issued by the CDC that didn't differentiate by age or risk factors. However, the European agencies in charge of vaccine approval, the EMA and MHRA, haven't suggested marketing authorization changes, such as narrowing the indication based on age, for any of the approved COVID-19 vaccines.
